Phase 3 trial results demonstrate the superiority of long-acting injectable cabotegravir + rilpivirine over daily oral ...
The agent, first approved in December for biweekly subcutaneous injection for EGFR-mutated NSCLC, showed similar efficacy and safety when administered monthly.
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides ...
Pharmaceutical Technology on MSN
J&J’s Rybrevant Faspro gains FDA approval for new dosing in NSCLC
The therapy dosing provides clinical outcomes consistent with those of the earlier approved bi-weekly subcutaneous regimen.
Accelerated approval can serve patients well—but only when surrogate endpoints are reliable and clearly predict outcomes that matter to patients.
According to Coherent Market Insights, The Global Alprostadil Injection Market is estimated to be valued at USD 212.4 Mn in 2025 and is expected to reach USD 347.8 Mn by 2032, exhibiting a compound ...
A cutting-edge gene therapy has significantly restored hearing in children and adults with congenital deafness, showing dramatic results just one month after a single injection. Researchers used a ...
A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, ...
Meitheal Pharmaceuticals recently launched two new generics. The company released alprostadil injection 500 mcg/ml single-dose vials to the U.S. market, where only an ampoule form is offered. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results